Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Expenses (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Operating Expenses for 4 consecutive years, with $53.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 15.91% to $53.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $228.8 million, a 35.78% increase, with the full-year FY2024 number at $201.1 million, up 12.87% from a year prior.
  • Operating Expenses was $53.8 million for Q3 2025 at Centessa Pharmaceuticals, down from $54.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $74.6 million in Q4 2024 to a low of $36.1 million in Q1 2024.
  • A 4-year average of $49.6 million and a median of $47.0 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: crashed 31.27% in 2023, then soared 77.44% in 2024.
  • Centessa Pharmaceuticals' Operating Expenses stood at $41.6 million in 2022, then grew by 1.03% to $42.0 million in 2023, then skyrocketed by 77.44% to $74.6 million in 2024, then dropped by 27.88% to $53.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Operating Expenses are $53.8 million (Q3 2025), $54.7 million (Q2 2025), and $45.8 million (Q1 2025).